Auto-antibodies against type I IFNs in > 10% of critically ill COVID-19 patients: a prospective multicentre study.

Romain ArrestierPaul BastardThibaut BelmondoGuillaume VoiriotTomas UrbinaCharles-Edouard LuytAdrian GervaisLucy BizienLauriane SegauxMariem Ben AhmedRaphaël BellaïcheTaï PhamZakaria Ait-HamouDamien RouxRaphael Clere-JehlElie AzoulayStéphane GaudryJulien MayauxNicolas FageHafid Ait-OufellaElsa MoncombleMélodie ParfaitKarim DorghamGuy GorochovArmand Mekontso-DessapFlorence Canoui-PoitrineJean-Laurent CasanovaSophie HueNicolas De Prost

Published in: Annals of intensive care (2022)

In ICU patients, auto-Abs against type I IFNs were found in at least 10% of patients with critical COVID-19 pneumonia. They were not associated with day 28 mortality.

Keyphrases

sars cov
end stage renal disease
coronavirus disease
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
type diabetes
risk factors
patient reported outcomes
coronary artery disease
patient reported